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Background: Serum procalcitonin levels have been used as a biomarker of invasive bacterial
infection and recently have been advocated to guide antibiotic therapy in patients with chronic
obstructive pulmonary disease (COPD). However, rigorous studies correlating procalcitonin
levels with microbiologic data are lacking. Acute exacerbations of COPD (AECOPD) have been
linked to viral and bacterial infection as well as noninfectious causes. Therefore, we evaluated
procalcitonin as a predictor of viral versus bacterial infection in patients hospitalized with
AECOPD with and without evidence of pneumonia.
Methods: Adults hospitalized during the winter with symptoms consistent with AECOPD
underwent extensive testing for viral, bacterial, and atypical pathogens. Serum procalcitonin
levels were measured on day 1 (admission), day 2, and at one month. Clinical and laboratory
features of subjects with viral and bacterial diagnoses were compared.
Results: In total, 224 subjects with COPD were admitted for 240 respiratory illnesses. Of
these, 56 had pneumonia and 184 had AECOPD alone. A microbiologic diagnosis was made in
76 (56%) of 134 illnesses with reliable bacteriology (26 viral infection, 29 bacterial infection,
and 21 mixed viral bacterial infection). Mean procalcitonin levels were significantly higher in
patients with pneumonia compared with AECOPD. However, discrimination between viral
and bacterial infection using a 0.25 ng/mL threshold for bacterial infection in patients with
AECOPD was poor.
Conclusion: Procalcitonin is useful in COPD patients for alerting clinicians to invasive bacterial
infections such as pneumonia but it does not distinguish bacterial from viral and noninfectious
causes of AECOPD.
Keywords: virus, bacterial infection, procalcitonin, chronic obstructive pulmonary disease,
bronchitis
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Guidelines from the Global Initiative for Chronic Obstructive Pulmonary Disease
(GOLD) recommend antibiotics for the treatment of moderate to severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD).1 Several meta-analyses
support these recommendations to reduce mortality and treatment failures.2 Although
purulent sputum and growth of a bacterial pathogen suggest infection, definitive causality with an AECOPD is difficult because patients may be chronically colonized.3,4
In addition, recent studies using molecular diagnostics indicate that a substantial
proportion of AECOPD are associated with viral infection.5,6 Accurate methods to
differentiate viral and bacterial respiratory infections to allow targeted antibiotic
therapy would be beneficial. Measurement of serum procalcitonin has been proposed
to discriminate bacterial infection from viral or noninfectious causes.7
International Journal of COPD 2012:7 127–135
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Procalcitonin is a calcitonin precursor that is normally
produced in neuroendocrine cells of the thyroid and lungs.
However, in response to bacterial infections, procalcitonin
is produced by cells throughout the body. 8,9 Stimuli of
procalcitonin include bacterial products, including endotoxin
and proinflammatory cytokines such as tumor necrosis
factor alpha, whereas procalcitonin is attenuated by viralinduced interferon-γ.8,10 Procalcitonin testing has been
used successfully as a guide to predict serious bacterial
infections and medical outcomes in patients with sepsis.11,12
Recently, procalcitonin has been assessed as a guide to
antibiotic therapy in patients with respiratory illnesses,
including COPD.7,13–18 However, microbiologic assessment
to prove the presence or absence of bacterial infection was
not performed in the majority of subjects in most trials,
which is a concern for the Food and Drug Administration
and Infectious Disease Society of America, as noted in a
recent workshop.19 Therefore, we examined the utility of
serum procalcitonin levels as predictors of viral and bacterial
infection in patients hospitalized with AECOPD using
rigorous viral and bacteriologic studies.

Methods
Patient population
The study was performed at Rochester General Hospital,
a 520-bed general medical-surgical hospital located in
Rochester (Monroe County), NY. Subjects were participating
in a larger ongoing study of the relationship between procalcitonin level and definitive bacterial and viral diagnosis (to
be described in a separate publication). Adults $21 years
of age admitted through the Emergency Department to
Rochester General Hospital with an admitting diagnosis
compatible with acute respiratory tract infection were
recruited from November 1 to May 30 during 2008–2009
and 2009–2010. A subset of subjects with a past medical
history of COPD and smoking and symptoms consistent with
AECOPD according to the GOLD criteria (increased dyspnea,
cough, and/or increased sputum volume or purulence) were
identified for the present analysis. Confirmation of COPD
was sought as available in the hospital medical records.
Patients were screened within 24 hours of admission and
those given antibiotics prior to admission, or who had
immunosuppression, cavitating lung disease, or witnessed
aspiration were excluded.20 In addition, subjects with other
conditions known to increase serum procalcitonin levels
(burns, trauma, pancreatitis, renal failure, thyroid tumors)
were excluded from the study. Subjects or legal guardians
provided written informed consent. The study was approved
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by the University of Rochester and Rochester General
Hospital institutional review boards.

Illness evaluation
At enrollment, demographic, clinical, and laboratory
information was collected. Chest radiographs were classified by a pulmonary specialist as infiltrate or no infiltrate.
Testing for bacterial pathogens included: blood cultures,
sputum culture, and Gram stain; nose and throat swabs for
Mycoplasma pneumoniae and Chlamydophila pneumoniae
polymerase chain reaction; and urine for Streptococcus
pneumoniae antigen and pneumococcal serology. Sputum
was induced with normal saline if subjects were unable to
expectorate an adequate sputum sample spontaneously.
Specimens were considered adequate by standard criteria
of .25 polymorphonuclear leukocytes and ,10 epithelial
cells per high power field. Nose and throat swabs and sputum
were tested for viruses by reverse transcriptase polymerase
chain reaction. Sera were collected on hospital day 1 (prior
to antibiotics) and 4–6 weeks later for viral serology, pneumococcal serology, and procalcitonin measurements. Serum
was also collected on hospital days 2 and 28 for procalcitonin
measurement.

Laboratory methods
Standard microbiological testing including blood cultures,
sputum Gram stain and culture, influenza antigen testing,
and viral cultures were performed by the Rochester General
Hospital clinical laboratory. Sputum samples were plated on
blood, chocolate, and MacConkey agar. Legionella testing
was performed at the discretion of the treating physician.
Pneumococcal surface protein A antigens covering families
1 and 2, obtained from the University of Alabama Bacterial
Respiratory Pathogen Reference Laboratory, were used in
an enzyme immunoassay.21 A $4-fold rise in titer was considered evidence of infection. Urine samples were assayed
for pneumococcal antigen using BinaxNOW® (Binax Inc,
Scarborough, ME) urine assay.22

Procalcitonin
Procalcitonin was measured by resolved amplified cryptate
emission technology (Kryptor PCT, Brahms, Henningsdorf,
Germany). Functional sensitivity is 0.06 ng/mL (normal
0.033 ± 0.003 ng/mL).12,23,24 Immunoglobulin G titers in
acute and convalescent serum for each virus was determined using established EIA methods.25 A $4-fold rise in
viral specific immunoglobulin G was considered evidence
of infection.
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Real-time polymerase chain reaction
Assays for respiratory syncytial virus, human metapneumovirus, M. pneumoniae, and C. pneumoniae used published
methods.25–27 Primers and probes for other viruses were as
follows: influenza A (matrix gene), influenza B (nonstructural
1 [NS1] gene), coronaviruses (polymerase gene), and
parainfluenza viruses (nucleocapsid gene). Sequences can be
supplied on request. Bacteriology was considered unreliable
if sputum was not obtained or was obtained after 6 hours
of antibiotics, or was of inadequate quality. Subjects were
not considered to be viral infection alone or no infectious
diagnosis unless “reliable” bacteriology was negative.

Statistical analysis
Fisher’s Exact and t-tests were used to compare distributions
of categorical and continuous clinical variables for pneumonia
versus AECOPD patients. Differences in procalcitonin levels
were evaluated using the Wilcoxon test, summarized using
both means and standard deviations and medians with interquartile range, and receiver operator curves were plotted and
area under the curve tabulated. Multiple logistic regression was
used to model maximum (procalcitonin over days 1–2) $0.25
as a function of clinical covariates. SAS 9.2 was used for all
analyses, with tests performed at the two-sided 0.05 level.

Results
Enrollment and microbiology

with symptoms of AECOPD. Of these 224 subjects, 213 had
a single illness, 12 had two, and one subject had three hospitalizations for a total of 240 illnesses evaluated. The average
time between AECOPD admissions for subjects with more than
one illness evaluation was 7 ± 4 months. A diagnosis of COPD
was confirmed by pulmonary function testing, pulmonary physician evaluation, or radiographic changes in 90% of subjects.
Chest radiographs on admission revealed pneumonia in 56 cases,
and 184 illnesses were considered to be AECOPD alone
(Figure 1). Bacteriology was considered reliable in 134 (56%)
of the 240 illnesses (104 AECOPD and 30 pneumonia). Notably,
47 viral infections alone (37 AECOPD and 10 pneumonia)
were excluded from further analyses of microbiology, primarily because sputum samples were collected more than 6 hours
after antibiotics had been started. No patient was bacteremic.
A variety of viral pathogens were identified and 45% were
associated with bacterial infection (Table 1). S. pneumoniae
(22 cases) was the most common bacterial organism identified
and was associated with viral infection in 13 (59%) and mixed
bacterial infection in three (14%). Of the 22 subjects with
pneumococcal infection, half had more than one positive test
(ie, sputum culture, pneumococcal serology, or urine antigen).
Of the 31 subjects considered to have bacterial infection based
on sputum culture alone, all had 3–4+ growth of a potential
pathogen and 87% had a consistent Gram stain.

Pneumonia procalcitonin analysis

During two winters from 2008 to 2010, we enrolled 532 subjects,
of whom 224 had a history of COPD and a respiratory illness

Procalcitonin values were measured on day 1 (admission),
day 2, and at one month convalescence. Mean procalcitonin

Illnesses in subjects with COPD
240

Pneumonia
56

AECOPD
184

Bacteriology

Bacteriology
Reliable
104

Not reliable
80

V
37

V
25

BV
16

B
16

None
47

Reliable
30

Not reliable
26

V
10

None
43

V
1

BV
5

B
13

None
16

None
11

Figure 1 Flow chart of patient groups. Bacteriology is divided into reliable and not reliable.
Abbreviations: V, viral alone; B, bacterial alone; BV, bacterial + viral; none, no microbiologic diagnosis; COPD, chronic obstructive pulmonary disease.
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Table 1 Microbiology in subjects with reliable bacteriology
Organism
Single organism infections
Influenza A
Influenza B
Respiratory syncytial virus
Human metapneumovirus
Parainfluenza viruses (1–3)
Coronaviruses (229E and OC43)
Streptococcus pneumoniae
Haemophilus influenzae
Moraxella catarrhalis
Staphylococcus aureus
Gram-negative rods
Mycoplasma pneumoniae
Chlamydophila pneumoniae
Multiple pathogen infections
Mixed viral
Viral + S. pneumoniae
Viral + other bacteria
S. pneumoniae + other bacteria
Mixed other bacteria

AECOPD
n = 104

Pneumonia
n = 30

5
0
7
1
3
8
2
4
1
1
4
0
0

0
0
0
0
0
1
4
1
1
3
2
2
0

1
9
7
4
0

0
3
2
0
0

Abbreviation: AECOPD, acute exacerbations of chronic obstructive pulmonary
disease.

values were higher in COPD patients with pneumonia
compared with those with AECOPD only (Table 2).
Procalcitonin values decreased signif icantly in both
groups at the convalescent time point. Using published
procalcitonin thresholds of $0.25 ng/mL as indicative of
possible, and $0.5 ng/mL as probable bacterial infection,
59% of pneumonia patients would have been classified
as possible and 48% as probable bacterial infection using
the maximum procalcitonin on either the day 1 or day 2
measurement.15,16

Clinical features

Because empiric antibiotics are recommended for all patients
with pneumonia, further analyses were restricted to those with
AECOPD only. In contrast with subjects with radiographic
evidence of pneumonia, only 31 of 184 (17%) in the AECOPD
group had procalcitonin values $0.25 ng/mL. Clinical features associated with a procalcitonin value , or $0.25 ng/mL
in the AECOPD group are shown in Table 3. Patients with
elevated procalcitonin values more often received inhaled or
oral steroids, had higher white blood cell levels, temperature,
intensive care unit admission rates, and CURB-65 scores.
Of note, the frequency of subjects having the three cardinal
symptoms warranting antibiotics, as defined by Anthonisen
criteria (increased dyspnea, sputum volume, sputum
purulence), were similar in the two groups, as were the rates
of documented bacterial infections. Clinical features were
evaluated by logistic regression [odds ratio (OR), 95% confidence interval (CI)] and elevated white blood cells (OR 1.2
[95% CI 1.1–1.3], P = 0.0004), temperature (OR 1.9 [95%
CI 1.2–3.0], P = 0.01). and ICU admission (OR 3.9 [95% CI
1.3–3.0], P = 0.01) remained significant associations.

Microbiology
Clinical features were not significantly different for AECOPD
due to viral infection alone compared with those with bacterial infection alone or mixed viral bacterial infection with the
exception of greater inhaled corticosteroid use in the bacterial infection alone + mixed viral bacterial infection group
(data not shown). Maximum procalcitonin values on day
1 or 2 in patients with bacterial infection (bacterial infection

Table 2 Procalcitonin values (ng/mL) of subjects with pneumonia compared with those with acute exacerbations of chronic obstructive
pulmonary disease
Study group and day
Hospital day 1 (admission)
Pneumonia (n = 56)
AECOPD (n = 181)
Hospital day 2
Pneumonia (n = 54)
AECOPD (n = 172)
Maximum on day 1 or 2
Pneumonia (n = 56)
AECOPD (n = 184)
Days 28–42
Pneumonia (n = 46)
AECOPD (n = 153)

Mean ± SD
ProCT ng/mL

Median (IQR)
ProCT ng/mL

Wilcoxon exact test

AUC (95% CI)

3.62 ± 17.38
0.39 ± 2.22

0.31 (1.29)
0.08 (0.07)

P , 0.0001

0.76 (0.68–0.84)

3.30 ± 10.32
0.49 ± 2.26

0.33 (0.69)
0.09 (0.09)

P , 0.0001

0.75 (0.67–0.82)

4.73 ± 17.92
0.52 ± 2.31

0.39 (2.33)
0.09 (0.01)

P , 0.0001

0.75 (0.67–0.83)

0.22 ± 0.47
0.12 ± 0.33

0.07 (0.09)
0.06 (0.06)

P = 0.22

0.56 (0.46–0.66)

Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; AUC, area under the concentration-time curve; CI, confidence interval;
IQR, interquartile range; ProCT, procalcitonin.
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Table 3 Clinical characteristics of subjects with nonpneumonic acute exacerbations of chronic obstructive pulmonary disease stratified
by procalcitonin values above and below 0.25 ng/mL

Age (mean ± SD)
Male (%)
Race, white
Diabetes
Congestive heart failure
Influenza vaccine
Pneumococcal vaccine
Chronic oral steroid use
Chronic inhaled steroid use
Home oxygen use
Symptoms (%)
Upper respiratory tract infection
Cough
Sputum production*
Purulent sputum*
Dyspnea*
Three Anthonisen criteria present
Rigors
Physical examination (%)
Wheezing
Rales
Rhonchi
Diaphoresis
Temperature (mean ± SD)
Respiratory rate (mean ± SD)
Oxygen saturation (mean ± SD)
White blood cells × 103/mL (mean ± SD)
% neutrophils (mean ± SD)
% band forms (mean ± SD)
CURB-65 score
Bacterial infection documented
Intensive care
Length of stay
Death

ProCT , 0.25 ng/mL
n = 153

ProCT $ 0.25 ng/mL
n = 31

P value

66.3 ± 12.3
83 (54)
131 (86)
52 (34)
47 (31)
108 (71)
144 (94)
25 (16)
83 (54)
63 (41)

68.8 ± 14.2
14 (45)
29 (90)
11 (35)
13 (42)
24 (74)
30 (97)
11 (35)
24 (77)
17 (55)

0.31
0.43
0.58
1.0
0.29
0.52
1.0
0.02
0.02
0.17

116 (76)
144 (94)
120 (78)
91 (59)
148 (97)
87 (57)
35 (23)

20 (65)
29 (94)
26 (84)
18 (58)
30 (97)
17 (55)
6 (19)

0.26
0.44
0.62
1.0
1.0
0.85
0.48

123 (80)
36 (24)
43 (28)
14 (9)
36.9 ± 0.7
26 ± 6
91.7 ± 6
10.4 ± 3.9
72 ± 13
1.5 ± 2.4
1.6 ± 1.0
24 (16)
12 (8)
7 ± 32
3 (2)

23 (74)
11 (35)
8 (26)
7 (23)
37.3 ± 1.2
27 ± 10
92.8 ± 5.1
14.2 ± 6.4
75 ± 16
2.8 ± 3.7
2.3 ± 1.0
8 (26)
8 (26)
8±9
1 (3)

0.48
0.18
1.0
0.06
0.01
0.17
0.31
0.0001
0.16
0.01
0.0002
0.20
0.008
0.93
0.52

Note: *Anthonisen criteria.
Abbreviations: SD, standard deviation; ProCT, procalcitonin.

alone + mixed viral bacterial infection) were compared with
those without bacterial infection (viral infection alone + no
pathogen identified) and were not significantly different
(Table 4, analysis A). Because procalcitonin is thought to be
attenuated by virally induced interferon, procalcitonin values
were compared for those having bacterial infection alone
with those having both bacterial and viral infection (Table 4,
analysis B). Procalcitonin values were slightly higher in
the mixed viral bacterial infection group compared with the
bacterial infection alone group, indicating that the presence
of concomitant viral infection does not significantly attenuate
the procalcitonin response in patients with dual infections.
Furthermore, among patients with known viral infection (viral
infection alone or mixed viral bacterial infection, Table 4,

International Journal of COPD 2012:7

analysis C), procalcitonin values were significantly higher
in the mixed viral bacterial infection group. Given the lack
of difference noted in analysis A, this finding might suggest
that the presence of a viral infection is necessary for invasive bacterial infection. Using the $0.25 ng/mL threshold,
the specificity for bacterial infection among patients with a
documented viral infection was 96% but sensitivity was low
at 31%, with a positive predictive value of 83% and negative
predictive value of 69% (Figure 2). Although a significant
difference in the mean and median procalcitonin values in this
group could be demonstrated, discrimination between viral
and bacterial coinfection by procalcitonin was poor (Figure 3).
Although only one of 25 patients with virus infection alone
would have been misclassified as possible bacterial infection,
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Table 4 Maximum day 1 or 2 serum ProCT values in subjects with acute exacerbations of chronic obstructive pulmonary disease and
reliable bacteriology
Analysis

Groups

Mean ± SD
ProCT ng/mL

Median (IQR)
ProCT ng/mL

Wilcoxon exact
test

AUC (95% CI)

A

Any bacterial
n = 32
Nonbacterial
n = 72
Bacterial alone
n = 16
Bacterial + virus
n = 16
Bacterial + virus
n = 16
Virus alone
n = 25

0.32 ± 0.57

0.10 (0.17)

P = 0.06

0.62 (0.49–0.74)

0.20 ± 0.66

0.08 (0.06)

0.17 ± 0.21

0.09 (0.09)

P = 0.06

0.70 (0.51–0.88)

0.46 ± 0.76

0.14 (0.25)

0.46 ± 0.76

0.14 (0.25)

P = 0.03

0.70 (0.53–0.87)

0.11 ± 0.07

0.09 (0.07)

B

C

Abbreviations: AUC, area under the concentration-time curve; CI, confidence interval; IQR, interquartile range; ProCT, procalcitonin.

11 of 16 patients (69%) with concomitant bacterial infection
would have been categorized as low risk of bacterial infection.
Interestingly, the single patient with a viral infection alone
and elevated procalcitonin levels had influenza complicated
by pericardial tamponade, necessitating surgical intervention
on the second hospital day. As demonstrated in Figure 3, most
subjects in any category (viral alone, viral + bacterial, or
bacterial alone) fell below the 0.25 ng/mL threshold on day
1 or 2 of hospitalization.

Discussion
Infection is a major cause of morbidity and mortality among
patients with COPD.28 In COPD patients presenting to the
Area under the curve = 0.7013
1.00

Sensitivity

0.75

0.50

0.25

0.00
0.00

0.25

0.50

0.75

1.00

1-specificity
Figure 2 Receiver operator curve for procalcitonin as a diagnostic tool for bacterial
infection in patients with a documented viral infection and acute exacerbations of
chronic obstructive pulmonary disease without pneumonia. Specificity is indicated
on y-axis and sensitivity on x-axis.
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hospital with dyspnea, our study demonstrates a wide variety
of viral and bacterial pathogens, as well as a high incidence
of pneumonia. Recently, use of procalcitonin to guide clinical
decisions has been shown to reduce antibiotic use significantly
in patients with respiratory illnesses without compromising
composite patient outcomes in a number of randomized
interventional trials.13–18,29 Although procalcitonin-guided
decisions have been promulgated as a method to “rule out”
bacterial infection, the 0.25 ng/mL threshold for recommending antibiotic treatment is not based on microbiologic data.
Recovery without antibiotics or with an abbreviated course
has been equated with the absence of a bacterial infection.
The lack of microbiologic correlation with procalcitonin
levels is likely to slow endorsement of procalcitonin-guided
management in respiratory illness.19,30,31
Ours is the first study in the US to examine the utility of
procalcitonin levels in patients with COPD, and consistent
with the European literature, we found that a high procalcitonin level was relatively specific for invasive bacterial
disease such as pneumonia.32,33 In addition, elevated procalcitonin values in the AECOPD group correlated with higher
temperature, white blood cells, and more severe illness,
suggesting the possibility of occult pneumonia. Thus, high
procalcitonin values may alert clinicians to the presence of
bacterial pneumonia when the chest radiograph results are
negative or ambiguous.
However, our results also indicate that minor elevations at
the low end of the procalcitonin spectrum do not correlate with
bacterial infection for subjects with AECOPD alone. It has
been estimated that approximately 40%–50% of AECOPD
cases are due to bacterial infections.34 The precise contribution of bacterial infection is difficult to define because the
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10.00

ng/mL

1.00
0.50
0.25

0.10

0.01

V1

V2

V3

BV1

BV2

BV3

B1

B2

B3

Figure 3 Procalcitonin values in subjects with acute exacerbations of chronic obstructive pulmonary disease without pneumonia. Individual procalcitonin values expressed as
ng/mL on a log 10 scale. Viral alone patients are shown on admission (V1), day 2 (V2), and day 28 (V3) and bacterial + viral are shown on admission (BV1), day 2 (BV2), and
day 28 (BV3) and bacterial alone on admission (B1), day 2 (B2), and day 28 (B3). The 0.25 ng/mL and 0.50 ng/mL procalcitonin levels are indicated by the dotted lines.

airways of COPD patients may be chronically colonized.3,4
Acquisition of new strains of Haemophilus influenzae and
Moraxella catarrhalis, rather than bacterial load, appears
to be the most important factor in the pathogenesis of acute
exacerbations.35 This factor has not been accounted for in
AECOPD antibiotic trials and might explain the modest
beneficial effects of antimicrobial treatments observed.
We accept that some subjects who were classified as
having bacterial infection in our study were colonized
rather than infected. However, only 17% of patients overall
with AECOPD and without pneumonia, and only 25% of
those with evidence of bacterial infection had procalcitonin
levels $0.25 ng/mL. While it is possible that this small
subgroup represents those who will actually benefit from
antibiotic treatment, such a conclusion is premature. Notably,
of those with procalcitonin levels ,0.25 ng/mL, 57% had
three Anthonisen criteria, suggesting they would benefit
from antibiotic treatment based on past studies.36 Thus, only
two conclusions are possible, ie, either the contribution of
bacterial infection in AECOPD has been markedly overestimated or procalcitonin values do not differentiate bacterial
bronchitis from viral or noninfectious etiologies.
Our study adds to the growing body of literature which
questions the utility of procalcitonin levels to discriminate
viral-associated from bacterial-associated AECOPD. In a
study by Daniels et al, procalcitonin levels were measured in
outpatients enrolled in a trial of doxycycline for AECOPD.37
A significant benefit of doxycycline was noted for patients
with procalcitonin levels ,0.1 ng/mL. In this study, as well as

International Journal of COPD 2012:7

in two additional reports, no differences in procalcitonin levels were noted in patients with or without bacteria in sputum
during exacerbation.32,37,38 Our study provides the most
rigorous microbiologic analysis of moderate to severe illness
requiring hospitalization to date, particularly for subjects who
were deemed negative for bacterial infection. Unlike prior
studies, we did not consider patients to be free of bacterial
infection unless adequate samples were taken in a timely
fashion and without antibiotic use prior to hospitalization.
Our study had several limitations. The number of patients
with documented bacterial infection was relatively small.
However, large numbers of subjects are not needed to show
that a test is insensitive, especially if missing even a few
patients with potentially treatable bacterial infections is
considered unacceptable. Because medical information was
restricted to that available in the hospital medical record, we
could not classify the stage of COPD using GOLD criteria
in our subjects. Lastly, we did not test for rhinovirus, a common pathogen in this population, although this omission does
not invalidate the findings for those patients with a viral or
bacterial infection identified.
In conclusion, we found that elevated serum procalcitonin
levels are associated with more severe illness in patients
hospitalized with symptoms of AECOPD and that high
values may alert clinicians to the possibility of pneumonia.
However, low procalcitonin values do not “rule out” bacterial
infection in AECOPD. Before procalcitonin-based treatment
algorithms are endorsed, additional studies in COPD patients
should be performed. Clinical trials focusing on antibiotic
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benefit are needed specifically in patients with nonpneumonic
exacerbations associated with low procalcitonin values.
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